Martin Boegemann (Martin Bögemann, Martin Bogemann)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 11

Top Topics

Diffusion Weighted

Prostate Cancer

Radical Prostatectomy

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Maha H A Hussain, Bertrand Tombal, Fred Saad, Karim Fizazi, Cora N Sternberg, E David Crawford, Neal D Shore, Evgeny Kopyltsov, Arash Rezazadeh Kalebasty, Martin Boegemann, Dingwei Ye, Felipe José Silva Melo Cruz, Hiroyoshi Suzuki, Shivani Kapur, Shankar Srinivasan, Frank Verholen, Iris Kuss, Heikki Joensuu, Matthew R Smith
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Okyaz Eminaga, Timothy Jiyong Lee, Mark Laurie, T Jessie Ge, Vinh La, Jin Long, Axel Semjonow, Martin Boegemann, Hubert D Lau, Eugene Shkolyar, Lei Xing, Joseph C Liao
Efficient Augmented Intelligence Framework for Bladder Lesion Detection. JCO clinical cancer informatics 7 (2023)
Robert Seifert, Sazan Rasul, Konstantin Seitzer, Maria Eveslage, Laya Rahbar Nikoukar, Katharina Kessel, Michael Schäfers, Josef Yu, Alexander R Haug, Marcus Hacker, Martin Boegemann, Lisa Bodei, Michael J Morris, Michael S Hofman, Kambiz Rahbar
A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. Radiology (2023)
Aurelius G Omlin, Richard Cathomas, Gunhild von Amsberg, Christoph Reuter, Susan Feyerabend, Wolfgang Loidl, Martin Boegemann, Anja Lorch, Axel Heidenreich, Igor Tsaur, Julian Larcher-Senn, Stefan A J Buck, Ron H J Mathijssen, Ulrich Jaehde, Silke Gillessen Sommer, Markus Joerger
Randomized phase 2 Cabazitaxel dose individualization and Neutropenia prevention Trial (CAINTA) in patients with metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Elisabeth Relt, Wolfgang Roll, Michael Claesener, Martin Boegemann, Matthias Weckesser, Kambiz Rahbar
Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [ 18 F]F-PSMA 1007 PET. Cancers 14 (20) (2022)
Christian Doehn, Martin Boegemann, Viktor Gruenwald, Manfred Welslau, Jens Bedke, Martin Schostak, Thomas Wolf, Rainer Ehneß, Elisa Degenkolbe, Stefanie Witecy, Peter J Goebell
The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape. Cancers 14 (22) (2022)
Okyaz Eminaga, Eugene Shkolyar, Bernhard Breil, Axel Semjonow, Martin Boegemann, Lei Xing, Ilker Tinay, Joseph C Liao
Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based Study. Cancers 14 (13) (2022)
Wolfgang Roll, Philipp Schindler, Max Masthoff, Robert Seifert, Katrin Schlack, Martin Boegemann, Lars Stegger, Matthias Weckesser, Kambiz Rahbar
Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis. Cancers 13 (15) (2021)
Katharina Kessel, Christof Bernemann, Martin Boegemann, Kambiz Rahbar
Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management. Cancers 13 (14) (2021)
Konstantin Egon Seitzer, Robert Seifert, Katharina Kessel, Wolfgang Roll, Katrin Schlack, Martin Boegemann, Kambiz Rahbar
Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives. Cancers 13 (15) (2021)
Martin Boegemann, Sara Khaksar, Guillaume Bera, Alison Birtle, Catherine Dopchie, Louis-Marie Dourthe, Els Everaert, Martin Hatzinger, Dirko Hercher, Werner Hilgers, Geoffrey Matus, Laura Garcia Alvarez, Laurent Antoni, Martin Lukac, Geneviève Pissart, Paul Robinson, Tony Elliott
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study. BMC cancer 19 (1) (2019)